Sangamo Q1 net loss $31M; cash only into Q3 2026; stock delisted to OTCQB

SANGAMO THERAPEUTICS, INC

2026-Q1 EPS reported -$0.08 revenue$1,442,000

Q1 2026 net loss $31.0M ($0.08/share) vs $30.6M loss in Q1 2025; revenue dropped to $1.4M from $6.4M.
Cash and cash equivalents $27.6M as of March 31 – expects to fund operations only into Q3 2026.
Common stock delisted from Nasdaq, now trading on OTCQB; hearing to appeal delisting scheduled June 9.
Rolling BLA for Fabry gene therapy ST-920 underway; CMC module completion expected summer 2026 subject to funding.
2026 GAAP operating expense guidance $110M-$130M; company warns guidance depends on securing additional funding.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SANGAMO THERAPEUTICS, INC reported first quarter ended March 31, 2026 results: revenue $1.4 million, net income $31.0 million, EPS $0.08 per share.

Period: first quarter ended March 31, 2026
Revenue: $1.4 million
Net income: $31.0 million
EPS: $0.08 per share
Result: reported results

Exact text from the filing

First Quarter 2026 Financial Results Consolidated net loss for the first quarter ended March 31, 2026 was $31.0 million, or $0.08 per share, compared to a consolidated net loss of $30.6 million, or $0.14 per share, for the same period in 2025. Revenues Revenues for the first quarter ended March 31, 2026 were $1.4 million, compared to $6.4 million for the same period in 2025.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

SANGAMO THERAPEUTICS, INC filing history →

Source: SEC EDGAR

accession 0001628280-26-035061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.